IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 149 filers reported holding IMMUNOVANT INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,702,101 | +103.6% | 96,434 | +0.6% | 0.03% | +93.8% |
| Q2 2023 | $1,818,388 | +36.6% | 95,856 | +11.7% | 0.02% | +33.3% |
| Q1 2023 | $1,330,960 | -14.4% | 85,813 | -2.0% | 0.01% | -14.3% |
| Q4 2022 | $1,554,332 | +337.8% | 87,568 | +37.5% | 0.01% | +366.7% |
| Q3 2022 | $355,000 | +31.5% | 63,672 | -7.9% | 0.00% | 0.0% |
| Q2 2022 | $270,000 | -59.0% | 69,110 | -42.2% | 0.00% | -57.1% |
| Q1 2022 | $659,000 | -41.9% | 119,625 | -10.1% | 0.01% | -46.2% |
| Q4 2021 | $1,134,000 | -7.4% | 133,092 | -5.6% | 0.01% | +8.3% |
| Q3 2021 | $1,225,000 | -10.2% | 140,952 | +9.2% | 0.01% | 0.0% |
| Q2 2021 | $1,364,000 | -52.0% | 129,048 | -27.2% | 0.01% | -57.1% |
| Q1 2021 | $2,843,000 | -60.9% | 177,246 | +12.6% | 0.03% | -65.9% |
| Q4 2020 | $7,270,000 | – | 157,400 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |